Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
Active, not recruiting · NCT05696548 · Registry updated 2026-04-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, thyroid gland undifferentiated (anaplastic) carcinoma | Active, not recruiting | Phase 2 | 2026-04-09 | NCT05696548 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Center Hospital East | 10 |
| Ono Pharmaceutical Co., Ltd. | 47 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aichi Cancer Center | Nagoya | Japan | 23 |
| Hokkaido University Hospital | Hokkaido | Japan | 1 |
| Hyogo Cancer Center | Akashi | Japan | 17 |
| Kobe University Hospital | Kobe | Japan | 28 |
| National Cancer Center Hospital | Tokyo | Japan | 4 |
| National Cancer Center Hospital East | Kashiwa | Japan | 67 |
| Nippon Medical School Hospital | Tokyo | Japan | 2 |
| Osaka Metropolitan University Hospital | Osaka | Japan | 14 |
| Tohoku University Hospital | Sendai | Japan | 55 |
| Yokohama City University Hospital | Yokohama | Japan | 21 |